Proteomics International Laboratories Ltd

ASX:PIQ Stock Report

Market Cap: AU$85.2m

Proteomics International Laboratories Valuation

Is PIQ undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

0/6

Valuation Score 0/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of PIQ when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate PIQ's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate PIQ's fair value for valuation analysis.


Key Valuation Metric

Which metric is best to use when looking at relative valuation for PIQ?

Other financial metrics that can be useful for relative valuation.

PIQ key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue24x
Enterprise Value/EBITDA-12.9x
PEG Ration/a

Price to Sales Ratio vs Peers

How does PIQ's PS Ratio compare to its peers?

The above table shows the PS ratio for PIQ vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PSEstimated GrowthMarket Cap
Peer Average11.9x
OSL OncoSil Medical
33.8xn/aAU$53.0m
CTE Cryosite
3.4xn/aAU$43.0m
TRJ Trajan Group Holdings
1.2x6.0%AU$188.8m
GSS Genetic Signatures
9.2x41.9%AU$127.1m
PIQ Proteomics International Laboratories
26x40.2%AU$85.2m

Price-To-Sales vs Peers: PIQ is expensive based on its Price-To-Sales Ratio (26x) compared to the peer average (11.9x).


Price to Earnings Ratio vs Industry

How does PIQ's PE Ratio compare vs other companies in the Global Life Sciences Industry?

0 CompaniesPrice / EarningsEstimated GrowthMarket Cap
Industry Avg.n/a19.7%
n/an/an/a
No. of CompaniesPS048121620

Fetching data

0 CompaniesPrice / EarningsEstimated GrowthMarket Cap
Industry Avg.n/a19.7%
n/an/an/a
No more companies

Price-To-Sales vs Industry: PIQ is expensive based on its Price-To-Sales Ratio (26x) compared to the Global Life Sciences industry average (4.1x).


Price to Sales Ratio vs Fair Ratio

What is PIQ's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

PIQ PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio26x
Fair PS Ratio6.6x

Price-To-Sales vs Fair Ratio: PIQ is expensive based on its Price-To-Sales Ratio (26x) compared to the estimated Fair Price-To-Sales Ratio (6.6x).


Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.


Discover undervalued companies